Early Effects of Dexamethasone Implant on Macular Morphology and Visual Function in Patients with Macular Edema Secondary to Retinal Vein Occlusion

Veritti, Daniele; Macor, Sara; Lanzetta, Paolo

doi:10.1159/000366232

Cited by 12 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have shown clinically significant improvement and increased vision after the administration of the IDI injection in patients with RVO. [ 9 10 14 15 ] In the present study, the IDI injection decreased CFT value and increased BCVA value in both the BRVO and CRVO groups. Moreover, a significant difference was observed between pre- and post-injection CFT and BCVA values ( P < 0.001 and P < 0.001, respectively).…”

Section: Discussionsupporting

confidence: 53%

The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario

Şimşek

Çıtırık

Özateş

et al. 2018

Indian J Ophthalmol

View full text Add to dashboard Cite

Purpose:This study evaluated the effect of intravitreal dexamethasone implant (IDI; Ozurdex) injection for treating macular edema in patients with branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).Methods:This prospective study included 40 eyes of 40 patients with nonischemic BRVO and 31 eyes of 31 patients with nonischemic CRVO who received IDI injection as the first-line treatment for macular edema. The best-corrected visual acuity (BCVA) value before and after the treatment; intraocular pressure; optic coherence tomography findings; and all ocular examination findings, including central foveal thickness (CFT) measurement and fluorescein angiography findings, were evaluated for each patient.Results:After the IDI injection, BCVA value increased (P < 0.001) and CFT value decreased (P < 0.001) in both groups. The recurrence rates of CFT elevation after the first and the second Ozurdex injections were 65.0% and 65.3%, respectively, in patients with BRVO and 70.9% and 68.1%, respectively, in patients with CRVO. A statistically significant correlation was observed between preinjection CFT value and postinjection recurrence of CFT elevation (P = 0.017).Conclusion:Treatment with the IDI injections resulted in significant short-term improvement in CFT and BCVA values in patients with clinically significant RVO-related macular edema. Moreover, we observed that high preinjection CFT value was associated with a risk of postinjection recurrence of CFT elevation.

show abstract

Section: Discussionsupporting

confidence: 53%

The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario

Şimşek

Çıtırık

Özateş

et al. 2018

Indian J Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Our findings of a significant reduction in CMT after 3 h support the hypothesis that intravitreal long-release steroids play a role in humans, inducing a rapid response in terms of reduction of CMT. Veritti investigated the effect of dexamethasone implants on macular morphology and visual function in eyes with RVO [25] and DME [26]. In both pathologies, a fast reduction in macular thickness was seen, starting 1 day after the administration of the drug.…”

Section: Discussionmentioning

confidence: 99%

Short-Term Assessment of Intravitreal Dexamethasone Implant Using Enhanced-Depth Image Optical Coherence Tomography and Optical Coherence Tomography Angiography in Patients with Retinal Vascular Diseases

et al. 2018

View full text Add to dashboard Cite

IntroductionTo evaluate the short-term efficacy and safety of intravitreal dexamethasone implant (IDI) in patients with macular oedema associated with diabetic retinopathy (DR) and retinal vein occlusion (RVO) using enhanced-depth image optical coherence tomography (EDI-OCT) and to estimate the effect of dexamethasone on the choroid and the retinal vascular network using OCT angiography (OCTA).MethodsFifteen eyes in 15 patients with macular oedema secondary to diabetes (DR, n = 8) or retinal vein occlusion (RVO, n = 7) were treated with intravitreal injection of sustained-release IDI. Primary efficacy end points were changes in best corrected visual acuity and central macular thickness (CMT). Secondary end points were changes in choroidal thickness and choroidal and retinal vascular networks as determined by OCTA.ResultsCMT was significantly reduced from baseline by 3 h after injection (p < 0.01) and improved further during the 3-month follow-up. Visual acuity improvement was consistent with CMT reduction. No alterations in IOP or systemic side effects were observed. OCTA showed improvement from baseline in terms of decreased number and size of cysts and restoration of the retinal vascular network; flow choroidal thickness did not change significantly. CMT and visual acuity variations were similar in the two groups.ConclusionsCMT reduced as early as 3 h after the injection of IDI, with further reduction during follow-up. Choroidal thickness was unchanged, whereas the vascular retinal network improved from baseline to the end of study. Both EDI-OCT and OCTA were useful in demonstrating the early beneficial effects of IDI on the macula and the perifoveal vascular network.FundingThe article processing charges, the open access fee and the medical writing and editorial assistance was funded by Allergan.

show abstract

“…Also, some studies whose final outcome was not BCVA and CRT, the results were not reported, and patients had already received other treatments were also excluded. Finally, seven eligible studies including 393 eyes were used in the present meta-analysis [7][8][9][10][11][12]. The flow chart for the study selection process is shown in Figure 1.…”

Section: Search Resultsmentioning

confidence: 99%

Safety and effectiveness of intravitreal injection of dexamethasone for macular edema secondary to retinal vein occlusion: a meta-analysis

He¹,

Gao²,

Dan³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: This meta-analysis aimed to investigate the efficacy and safety of intravitreal injection of dexamethasone (DEX) in treating macular edema secondary to retinal vein occlusion. Method: PubMed, Embase-clinical key, clinicaltrials.gov, Web of Science, and SinoMed were searched to compare the application of DEX implant in patients with retinal vein occlusion secondary macular edema (RVO-ME). The central retinal thickness, best-corrected visual acuity (BCVA), postoperative intraocular pressure, and postoperative cataract were extracted. RevMan 5.3 was used to analyze and evaluate the data. Results: This study was based on six randomized trials. A total of 393 eyes were studied. DEX implant could effectively reduce macular edema caused by retinal vein occlusion. After 6 months, the drug could significantly improve the patients’ BCVA [95% confidence interval (CI), 9.669–21.649, P = 21.649]. At the same time, it also could significantly reduce the patients’ central retinal thickness (95% CI: 274.965–142.236, P = 0.0000). DEX implant could increase the intraocular pressure in some patients and greatly increase the risk of cataracts. Conclusions: DEX implant can effectively improve the BCVA of patients with RVO-ME, reduce the central thickness of the retina, and reduce the number of injections for a relatively long time. Therefore, intravitreal injection of DEX can be used as an effective method for treating RVO-ME.

show abstract

Early Effects of Dexamethasone Implant on Macular Morphology and Visual Function in Patients with Macular Edema Secondary to Retinal Vein Occlusion

Cited by 12 publications

References 21 publications

The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario

The efficacy of intravitreal dexamethasone implant as the first-line treatment for retinal vein occlusion-related macular edema in a real-life scenario

Short-Term Assessment of Intravitreal Dexamethasone Implant Using Enhanced-Depth Image Optical Coherence Tomography and Optical Coherence Tomography Angiography in Patients with Retinal Vascular Diseases

Safety and effectiveness of intravitreal injection of dexamethasone for macular edema secondary to retinal vein occlusion: a meta-analysis

Contact Info

Product

Resources

About